CA2168656C - A method for preparation of vesicles loaded with biological structures, biopolymers and/or oligomers - Google Patents

A method for preparation of vesicles loaded with biological structures, biopolymers and/or oligomers Download PDF

Info

Publication number: CA2168656C
Authority: CA; Canada
Prior art keywords: biopolymers; oligomers; structures; fraction; vesicles
Prior art date: 1993-08-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA002168656A

Other languages

English (en)

French (fr)

Other versions

CA2168656A1 (en

Inventor

Yechezkel Barenholz

Israel Nur

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Opperbas Holding BV

Original Assignee

Opperbas Holding BV

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-08-06

Filing date

1994-07-08

Publication date

2007-09-18

1994-07-08 Application filed by Opperbas Holding BV filed Critical Opperbas Holding BV

1994-07-08 Priority claimed from PCT/EP1994/002242 external-priority patent/WO1995004523A1/en

1995-02-16 Publication of CA2168656A1 publication Critical patent/CA2168656A1/en

2007-09-18 Application granted granted Critical

2007-09-18 Publication of CA2168656C publication Critical patent/CA2168656C/en

2014-07-08 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 54
229920001222 biopolymer Polymers 0.000 title claims abstract description 36
238000002360 preparation method Methods 0.000 title claims abstract description 24
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 23
239000000463 material Substances 0.000 claims abstract description 16
239000012736 aqueous medium Substances 0.000 claims abstract description 15
238000001035 drying Methods 0.000 claims abstract description 14
239000003960 organic solvent Substances 0.000 claims abstract description 13
239000000203 mixture Substances 0.000 claims description 37
150000002632 lipids Chemical class 0.000 claims description 29
150000003904 phospholipids Chemical class 0.000 claims description 24
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 23
229940067631 phospholipid Drugs 0.000 claims description 21
239000000427 antigen Substances 0.000 claims description 15
108091007433 antigens Proteins 0.000 claims description 15
102000036639 antigens Human genes 0.000 claims description 15
239000003814 drug Substances 0.000 claims description 14
238000009472 formulation Methods 0.000 claims description 14
239000000126 substance Substances 0.000 claims description 13
108090000623 proteins and genes Proteins 0.000 claims description 12
238000011282 treatment Methods 0.000 claims description 12
CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 claims description 11
230000000694 effects Effects 0.000 claims description 11
239000011780 sodium chloride Substances 0.000 claims description 11
229960003724 dimyristoylphosphatidylcholine Drugs 0.000 claims description 10
229960005160 dimyristoylphosphatidylglycerol Drugs 0.000 claims description 10
BPHQZTVXXXJVHI-AJQTZOPKSA-N ditetradecanoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-AJQTZOPKSA-N 0.000 claims description 10
102000004169 proteins and genes Human genes 0.000 claims description 10
230000003381 solubilizing effect Effects 0.000 claims description 10
238000002156 mixing Methods 0.000 claims description 9
210000003705 ribosome Anatomy 0.000 claims description 8
241001465754 Metazoa Species 0.000 claims description 6
239000002671 adjuvant Substances 0.000 claims description 6
150000003839 salts Chemical class 0.000 claims description 6
210000004027 cell Anatomy 0.000 claims description 5
239000003795 chemical substances by application Substances 0.000 claims description 5
239000006185 dispersion Substances 0.000 claims description 5
208000002672 hepatitis B Diseases 0.000 claims description 5
201000001441 melanoma Diseases 0.000 claims description 5
239000003981 vehicle Substances 0.000 claims description 5
244000068988 Glycine max Species 0.000 claims description 4
235000010469 Glycine max Nutrition 0.000 claims description 4
239000002577 cryoprotective agent Substances 0.000 claims description 4
210000002196 fr. b Anatomy 0.000 claims description 4
210000003918 fraction a Anatomy 0.000 claims description 4
239000003586 protic polar solvent Substances 0.000 claims description 4
229920006395 saturated elastomer Polymers 0.000 claims description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
206010042938 Systemic candida Diseases 0.000 claims description 3
239000013543 active substance Substances 0.000 claims description 3
210000003719 b-lymphocyte Anatomy 0.000 claims description 3
208000017773 candidemia Diseases 0.000 claims description 3
239000008101 lactose Substances 0.000 claims description 3
108020004707 nucleic acids Proteins 0.000 claims description 3
102000039446 nucleic acids Human genes 0.000 claims description 3
150000007523 nucleic acids Chemical class 0.000 claims description 3
-1 rRNA Proteins 0.000 claims description 3
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
108020005544 Antisense RNA Proteins 0.000 claims description 2
108010062466 Enzyme Precursors Proteins 0.000 claims description 2
102000010911 Enzyme Precursors Human genes 0.000 claims description 2
108090000790 Enzymes Proteins 0.000 claims description 2
102000004190 Enzymes Human genes 0.000 claims description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
229930006000 Sucrose Natural products 0.000 claims description 2
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
230000023555 blood coagulation Effects 0.000 claims description 2
230000000295 complement effect Effects 0.000 claims description 2
239000003184 complementary RNA Substances 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
238000001415 gene therapy Methods 0.000 claims description 2
239000005556 hormone Substances 0.000 claims description 2
229940088597 hormone Drugs 0.000 claims description 2
210000000987 immune system Anatomy 0.000 claims description 2
238000007918 intramuscular administration Methods 0.000 claims description 2
108020004999 messenger RNA Proteins 0.000 claims description 2
239000002773 nucleotide Substances 0.000 claims description 2
125000003729 nucleotide group Chemical group 0.000 claims description 2
210000003463 organelle Anatomy 0.000 claims description 2
102000004196 processed proteins & peptides Human genes 0.000 claims description 2
108090000765 processed proteins & peptides Proteins 0.000 claims description 2
230000002685 pulmonary effect Effects 0.000 claims description 2
239000005720 sucrose Substances 0.000 claims description 2
210000002845 virion Anatomy 0.000 claims description 2
HMPCUFDKPHXUPF-UHFFFAOYSA-N 2-methylpropan-1-ol;2-methylpropan-2-ol Chemical group CC(C)CO.CC(C)(C)O HMPCUFDKPHXUPF-UHFFFAOYSA-N 0.000 claims 1
210000003850 cellular structure Anatomy 0.000 claims 1
229940068998 egg yolk phospholipid Drugs 0.000 claims 1
239000008344 egg yolk phospholipid Substances 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
239000002502 liposome Substances 0.000 description 85
229960005486 vaccine Drugs 0.000 description 40
229960004222 factor ix Drugs 0.000 description 19
102100022641 Coagulation factor IX Human genes 0.000 description 18
108010076282 Factor IX Proteins 0.000 description 18
102000000588 Interleukin-2 Human genes 0.000 description 17
108010002350 Interleukin-2 Proteins 0.000 description 17
241000699670 Mus sp. Species 0.000 description 17
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 16
210000004185 liver Anatomy 0.000 description 16
239000012528 membrane Substances 0.000 description 14
239000000523 sample Substances 0.000 description 12
239000000243 solution Substances 0.000 description 12
210000004072 lung Anatomy 0.000 description 11
230000004044 response Effects 0.000 description 9
239000000725 suspension Substances 0.000 description 9
239000002245 particle Substances 0.000 description 8
239000007864 aqueous solution Substances 0.000 description 7
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
238000009826 distribution Methods 0.000 description 6
238000004108 freeze drying Methods 0.000 description 6
239000000843 powder Substances 0.000 description 6
239000002691 unilamellar liposome Substances 0.000 description 6
108010054218 Factor VIII Proteins 0.000 description 5
102000001690 Factor VIII Human genes 0.000 description 5
238000003556 assay Methods 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
238000005538 encapsulation Methods 0.000 description 5
238000001125 extrusion Methods 0.000 description 5
235000010445 lecithin Nutrition 0.000 description 5
238000011068 loading method Methods 0.000 description 5
229940115256 melanoma vaccine Drugs 0.000 description 5
PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 4
125000002252 acyl group Chemical group 0.000 description 4
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 4
210000000988 bone and bone Anatomy 0.000 description 4
201000010099 disease Diseases 0.000 description 4
229940079593 drug Drugs 0.000 description 4
229960000301 factor viii Drugs 0.000 description 4
238000007710 freezing Methods 0.000 description 4
230000008014 freezing Effects 0.000 description 4
208000015181 infectious disease Diseases 0.000 description 4
239000002904 solvent Substances 0.000 description 4
238000003860 storage Methods 0.000 description 4
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
206010053567 Coagulopathies Diseases 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
JLPULHDHAOZNQI-JLOPVYAASA-N [(2r)-3-hexadecanoyloxy-2-[(9e,12e)-octadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC JLPULHDHAOZNQI-JLOPVYAASA-N 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
235000012000 cholesterol Nutrition 0.000 description 3
229940084484 cimetidine 800 mg Drugs 0.000 description 3
230000035602 clotting Effects 0.000 description 3
230000036571 hydration Effects 0.000 description 3
238000006703 hydration reaction Methods 0.000 description 3
230000003053 immunization Effects 0.000 description 3
238000002649 immunization Methods 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
239000000787 lecithin Substances 0.000 description 3
229940067606 lecithin Drugs 0.000 description 3
GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 3
239000008188 pellet Substances 0.000 description 3
239000011148 porous material Substances 0.000 description 3
238000011321 prophylaxis Methods 0.000 description 3
239000002510 pyrogen Substances 0.000 description 3
230000007704 transition Effects 0.000 description 3
108010039209 Blood Coagulation Factors Proteins 0.000 description 2
102000015081 Blood Coagulation Factors Human genes 0.000 description 2
102000002322 Egg Proteins Human genes 0.000 description 2
108010000912 Egg Proteins Proteins 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
238000007792 addition Methods 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
238000004220 aggregation Methods 0.000 description 2
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000003114 blood coagulation factor Substances 0.000 description 2
238000011088 calibration curve Methods 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
238000013375 chromatographic separation Methods 0.000 description 2
239000012141 concentrate Substances 0.000 description 2
230000001461 cytolytic effect Effects 0.000 description 2
239000003599 detergent Substances 0.000 description 2
238000011161 development Methods 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
235000013345 egg yolk Nutrition 0.000 description 2
210000002969 egg yolk Anatomy 0.000 description 2
235000013601 eggs Nutrition 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000007789 gas Substances 0.000 description 2
210000002216 heart Anatomy 0.000 description 2
229960002520 hepatitis vaccine Drugs 0.000 description 2
238000000265 homogenisation Methods 0.000 description 2
230000000887 hydrating effect Effects 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
230000006698 induction Effects 0.000 description 2
230000003993 interaction Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000002609 medium Substances 0.000 description 2
239000000693 micelle Substances 0.000 description 2
JMUHBNWAORSSBD-WKYWBUFDSA-N mifamurtide Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 description 2
229960005225 mifamurtide Drugs 0.000 description 2
210000000865 mononuclear phagocyte system Anatomy 0.000 description 2
238000005502 peroxidation Methods 0.000 description 2
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
150000008105 phosphatidylcholines Chemical class 0.000 description 2
239000000047 product Substances 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
238000004088 simulation Methods 0.000 description 2
238000005063 solubilization Methods 0.000 description 2
238000000527 sonication Methods 0.000 description 2
241000894007 species Species 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
WTBFLCSPLLEDEM-JIDRGYQWSA-N 1,2-dioleoyl-sn-glycero-3-phospho-L-serine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC WTBFLCSPLLEDEM-JIDRGYQWSA-N 0.000 description 1
244000291564 Allium cepa Species 0.000 description 1
235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
229930183010 Amphotericin Natural products 0.000 description 1
QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
208000007204 Brain death Diseases 0.000 description 1
241000222120 Candida <Saccharomycetales> Species 0.000 description 1
241000222122 Candida albicans Species 0.000 description 1
239000004971 Cross linker Substances 0.000 description 1
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
206010068516 Encapsulation reaction Diseases 0.000 description 1
206010015866 Extravasation Diseases 0.000 description 1
229910008015 Li-M Inorganic materials 0.000 description 1
239000000232 Lipid Bilayer Substances 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
235000021314 Palmitic acid Nutrition 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
230000005867 T cell response Effects 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
102100037582 Vesicular, overexpressed in cancer, prosurvival protein 1 Human genes 0.000 description 1
208000027276 Von Willebrand disease Diseases 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000012615 aggregate Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
230000000735 allogeneic effect Effects 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
229940009444 amphotericin Drugs 0.000 description 1
229960003942 amphotericin b Drugs 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000000843 anti-fungal effect Effects 0.000 description 1
230000000603 anti-haemophilic effect Effects 0.000 description 1
230000003127 anti-melanomic effect Effects 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229960004405 aprotinin Drugs 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
238000012742 biochemical analysis Methods 0.000 description 1
239000013060 biological fluid Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
229940095731 candida albicans Drugs 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
229960001231 choline Drugs 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
229960001380 cimetidine Drugs 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000012937 correction Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000002059 diagnostic imaging Methods 0.000 description 1
238000010586 diagram Methods 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000012154 double-distilled water Substances 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000036251 extravasation Effects 0.000 description 1
150000002190 fatty acyls Chemical group 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000012634 fragment Substances 0.000 description 1
238000003505 heat denaturation Methods 0.000 description 1
239000012456 homogeneous solution Substances 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
238000005984 hydrogenation reaction Methods 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
239000000367 immunologic factor Substances 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
230000002584 immunomodulator Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000036512 infertility Effects 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
101150018863 maa gene Proteins 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
208000021039 metastatic melanoma Diseases 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
239000002808 molecular sieve Substances 0.000 description 1
238000011580 nude mouse model Methods 0.000 description 1
235000021313 oleic acid Nutrition 0.000 description 1
150000002889 oleic acids Chemical class 0.000 description 1
238000012856 packing Methods 0.000 description 1
150000002943 palmitic acids Chemical class 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
150000003014 phosphoric acid esters Chemical class 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
238000004321 preservation Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
238000010008 shearing Methods 0.000 description 1
238000005549 size reduction Methods 0.000 description 1
238000004513 sizing Methods 0.000 description 1
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000011146 sterile filtration Methods 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000012360 testing method Methods 0.000 description 1
239000010409 thin film Substances 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
238000009827 uniform distribution Methods 0.000 description 1
208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 description 1
101150041325 vopp1 gene Proteins 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Landscapes

Medicinal Preparation (AREA)
Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Manufacturing Of Micro-Capsules (AREA)
Paper (AREA)

CA002168656A 1993-08-06 1994-07-08 A method for preparation of vesicles loaded with biological structures, biopolymers and/or oligomers Expired - Fee Related CA2168656C (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP93112643		1993-08-06
EP93112643.7		1993-08-06
PCT/EP1994/002242 WO1995004523A1 (en)	1993-08-06	1994-07-08	A method for preparation of vesicles loaded with biological structures, biopolymers and/or oligomers

Publications (2)

Publication Number	Publication Date
CA2168656A1 CA2168656A1 (en)	1995-02-16
CA2168656C true CA2168656C (en)	2007-09-18

Family

ID=8213144

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002168656A Expired - Fee Related CA2168656C (en)	1993-08-06	1994-07-08	A method for preparation of vesicles loaded with biological structures, biopolymers and/or oligomers

Country Status (5)

Country	Link
JP (1)	JPH09501168A (de)
AT (1)	ATE163541T1 (de)
AU (1)	AU7384894A (de)
CA (1)	CA2168656C (de)
DE (1)	DE69408852T2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SA95160463B1 (ar) *	1994-12-22	2005-10-04	استرا أكتيبولاج	مساحيق للاستنشاق
FR2814956B1 (fr) *	2000-10-06	2003-01-24	Seppic Sa	Nouvelle composition vaccinale, procede pour sa preparation, utilisation comme composition injectale en medecine humaine ou veterinaire et nouveau procede de conservation
WO2010074172A1 (ja) *	2008-12-24	2010-07-01	株式会社バイオメッドコア	リポソームの製造方法ならびにコレステロール溶解方法
DK3336082T3 (da) *	2011-06-08	2020-04-27	Translate Bio Inc	Spaltelige lipider
EP4007614A1 (de) *	2019-08-01	2022-06-08	Septodont ou Septodont SAS ou Specialites Septodont	Mit aktivem komplementfragment beladenes dreidimensionales biomaterial für die regeneration von zahngewebe und/oder anderem gewebe

1994
- 1994-07-08 AU AU73848/94A patent/AU7384894A/en not_active Abandoned
- 1994-07-08 JP JP7506168A patent/JPH09501168A/ja not_active Withdrawn
- 1994-07-08 AT AT94923713T patent/ATE163541T1/de not_active IP Right Cessation
- 1994-07-08 DE DE69408852T patent/DE69408852T2/de not_active Expired - Lifetime
- 1994-07-08 CA CA002168656A patent/CA2168656C/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
ATE163541T1 (de)	1998-03-15
DE69408852D1 (de)	1998-04-09
JPH09501168A (ja)	1997-02-04
CA2168656A1 (en)	1995-02-16
AU7384894A (en)	1995-02-28
DE69408852T2 (de)	1998-10-01

Legal Events

Date	Code	Title	Description
2001-07-06	EEER	Examination request
2011-07-08	MKLA	Lapsed

Publication	Publication Date	Title
US6066331A (en)	2000-05-23	Method for preparation of vesicles loaded with biological structures, biopolymers and/or oligomers
EP0713388B1 (de)	1999-05-06	Verfahren zur hohen beladung von vesikeln mit biopolymeren substanzen
US6156337A (en)	2000-12-05	Method for high loading of vesicles with biopolymeric substances
Frezard	1999	Liposomes: from biophysics to the design of peptide vaccines
US5716637A (en)	1998-02-10	Solid fat nanoemulsions as vaccine delivery vehicles
US5026557A (en)	1991-06-25	Adjuvant composition
Palekar-Shanbhag et al.	2020	Bilosomes: superior vesicular carriers
DE69131709T2 (de)	2000-05-25	Liposomen enthaltende impfstoffzusammensetzungen
KR20010030892A (ko)	2001-04-16	공동-동결건조보존방법을 이용한 펩티드/지질 복합체
CA2436348A1 (en)	2002-06-06	Preparation of large liposomes by infusion into peg
US6110492A (en)	2000-08-29	Immunogenic compositions
EP0831780B1 (de)	2006-03-29	Verbesserte liposomale formulierung
EP1019026B1 (de)	2005-01-12	Biologisch aktive verbindungen enthaltende multilamellare koaleszenzvesikel (mlcv)
JP3813439B2 (ja)	2006-08-23	脂質剤及びタンパク質を含む脂質粒子の医薬組成物の製造方法
AU2003205048B2 (en)	2009-02-26	Efficient liposomal encapsulation
EP0713387B1 (de)	1998-03-04	Herstellungsverfahren von mit biologischen strukturen, biopolymeren und/oder oligomeren beladenen vesikeln
Dijkstra et al.	1988	A procedure for the efficient incorporation of wild-type lipopolysaccharide into liposomes for use in immunological studies
Kersten et al.	1988	Immunogenicity of liposomes and iscoms containing the major outer membrane protein of Neisseria gonorrhoeae: influence of protein content and liposomal bilayer composition
Gregoriadis	2017	Liposomes as immunological adjuvants for peptide and protein antigens
DE69408852T2 (de)	1998-10-01	Herstellungsverfahren von mit biologischen strukturen, biopolymeren und/oder oligomeren beladenen vesikeln
US20060062839A1 (en)	2006-03-23	Efficient liposomal encapsulation under mild conditions
Crommelin et al.	2014	Liposomes
Bergers et al.	1993	Critical factors for liposome-incorporated tumour-associated antigens to induce protective tumour immunity to SL2 lymphoma cells in mice
GREGORIADIS	1995	1. LIPOSOMES AS IMMUNOLOGICAL ADJUVANTS
EP1523977A1 (de)	2005-04-20	Biologisch aktive Verbindungen enthaltende multilamellare Koaleszenzvesikel (MLCV)